Albumedix enters into collaboration agreement with Cell and Gene Therapy Catapult

Albumedix Ltd. (‘Albumedix’), an enabler of advanced therapies and the world leader in recombinant human albumin (rAlb), announced today that they have entered into a collaboration agreement with Cell and Gene Therapy Catapult (CGT Catapult) to investigate the use of Albumedix´ proprietary albumin-based solutions for advanced therapy applications, including viral vectors manufacturing.

Albumedix enters into collaboration agreement with Cell and Gene Therapy Catapult

This agreement reflects the continued efforts of Albumedix to engage with the industry and expand upon its knowledge in the field, and the CGT Catapult’s mission to drive the growth of the UK cell and gene therapy industry by helping cell and gene therapy organizations across the world translate early-stage research into commercially viable and investable therapies.

Albumedix´ Chief Executive Officer; Jonas Skjødt Møller commented on the collaboration:

“With a mission to empower excellence in advanced therapies, we are committed to continuously playing an integral part in enabling our customers to advance in a fast-moving industry. For us to do so, we continuously look at other industry leaders to establish collaborations.

"Continuing to learn from each other allows innovation in the market to advance, and Albumedix to support our customers with in-depth knowledge of how rAlb can uniquely benefit their therapies. Cell and Gene Therapy Catapult is the ideal partner; located in our own backyard here in the UK and with incredible skills, knowledge and drive to advance the cell and gene therapy industry we are excited about this collaboration”.

Matthew Durdy, Chief Executive Officer at Cell and Gene Therapy Catapult commented:

“The opportunity to collaborate with a leading company like Albumedix Ltd in order to assess and drive the potential of their latest technology is something that we embrace. The prospect of improving manufacturing of viral vectors such as Adeno-associated virus (AAV) through this exciting technology is something which could significantly benefit and advance the wider cell and gene therapy field.”

Activities under this agreement will be carried out both at the CGT Catapult facility in Braintree and at Albumedix’ new R&D center, with state-of-the-art laboratories specifically designed for the process optimization, characterization and formulation development of advanced therapies.

Get in contact today to learn more about Albumedix' recombinant human albumin products or potential collaboration opportunities.

About Albumedix – Dedicated to Better Health

Albumedix is a science-driven, life-science company focused on enabling the creation of superior biopharmaceuticals utilizing our recombinant human albumin products. We believe in empowering excellence to enable advanced therapies and facilitate otherwise unstable drug candidates reach patients worldwide. We are proud to be recognized as the world leader in recombinant human albumin with products and technologies used in clinical and marketed drugs by pharmaceutical and medical device companies worldwide. Headquartered in Nottingham, England with more than 100 people all committed to improving patient quality of life. We are just as passionate about albumin and albumin-enabled therapies today as we were when we started more than 35 years ago. For more information, please contact us today.

About Cell and Gene Therapy Catapult

The Cell and Gene Therapy Catapult was established as an independent centre of excellence to advance the growth of the UK cell and gene therapy industry, by bridging the gap between scientific research and full-scale commercialisation. With more than 330 employees focusing on cell and gene therapy technologies, it works with partners in academia and industry to ensure these life-changing therapies can be developed for use in health services throughout the world. It offers leading-edge capability, technology and innovation to enable companies to take products into clinical trials and provide clinical, process development, manufacturing, regulatory, health economics and market access expertise. Its aim is to make the UK the most compelling and logical choice for UK and international partners to develop and commercialise these advanced therapies. The Cell and Gene Therapy Catapult works with Innovate UK. For more information please visit ct.catapult.org.uk or https://www.gov.uk/government/organisations/innovate-uk

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Albumedix Ltd.. (2021, February 18). Albumedix enters into collaboration agreement with Cell and Gene Therapy Catapult. News-Medical. Retrieved on June 20, 2021 from https://www.news-medical.net/news/20210202/Albumedix-enters-into-collaboration-agreement-with-Cell-and-Gene-Therapy-Catapult.aspx.

  • MLA

    Albumedix Ltd.. "Albumedix enters into collaboration agreement with Cell and Gene Therapy Catapult". News-Medical. 20 June 2021. <https://www.news-medical.net/news/20210202/Albumedix-enters-into-collaboration-agreement-with-Cell-and-Gene-Therapy-Catapult.aspx>.

  • Chicago

    Albumedix Ltd.. "Albumedix enters into collaboration agreement with Cell and Gene Therapy Catapult". News-Medical. https://www.news-medical.net/news/20210202/Albumedix-enters-into-collaboration-agreement-with-Cell-and-Gene-Therapy-Catapult.aspx. (accessed June 20, 2021).

  • Harvard

    Albumedix Ltd.. 2021. Albumedix enters into collaboration agreement with Cell and Gene Therapy Catapult. News-Medical, viewed 20 June 2021, https://www.news-medical.net/news/20210202/Albumedix-enters-into-collaboration-agreement-with-Cell-and-Gene-Therapy-Catapult.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
You might also like... ×
Albumedix ground-breaking ceremony